Project Grant P01HL167668
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$5.2M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Milwaukee, WI 53226, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $601,677 to the University of Massachusetts for a research project titled "Multi-Scale Characterization of Antigen-Polymerized Immune Complexes Underlying Thrombotic Pathologies Triggered by Adenoviral-Vectored Vaccines". The project aims to study the mechanism behind a rare but dangerous side effect called vaccine-induced immune thrombotic...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $445,000.00 to The Children's Hospital Of Philadelphia Research Institute to conduct research on the role of neutrophil extracellular traps (NETs) in thromboinflammatory diseases. The key objectives are to: 1) characterize the role of NETs in immune homeostasis, 2) define the mechanism by which platelet factor 4 (PF4) and an Fc-modified antibody enhance NET-mediated...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $160,518 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Research Institute. The 5-year grant, which began on August 15, 2024, supports the development of the principal investigator into an independent researcher in the field of immune modulation cell therapy for critically ill children, particularly those who have undergone...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $151,523 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The Medical College of Wisconsin, Inc. to investigate the role of fibrinogen in regulating thromboinflammation in acute and chronic venous thrombosis. The project aims to use novel RNA therapy to selectively reduce circulating fibrinogen levels and evaluate its impact on thrombus formation, resolution, and vein wall remodeling in rodent and...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $810,875 to The Trustees of the University of Pennsylvania to develop two novel chimeric antigen receptor (CAR) T cell strategies to selectively deplete autoantibody-secreting B cells as a potential curative treatment for acquired thrombotic thrombocytopenic purpura (ITTP), a life-threatening autoimmune disorder. The award aims to conduct in-depth preclinical...
This Project Grant award of $1,165,276 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will fund research to develop a novel biotherapeutic immunocytokine, F5111-IC, to suppress inhibitor formation in hemophilia patients. The primary awardee, Trustees of Indiana University, will investigate the F5111-IC treatment platform to promote immune tolerance and prevent the development of neutralizing antibodies against clotting factor replacement therapy...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, supports research to define the impact of platelet ABO(H) blood group antigens on hemostasis and thrombosis. The $445,708 award to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, will fund a 3-year project to: 1) Quantify the binding kinetics of von Willebrand Factor to platelets of different ABO blood types using ELISA...
This $225,600 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to engineer a lab-on-a-particle platform to measure platelet function. The primary objective is to design elastic hydrogel microparticles that can assess platelet adhesion, activation, aggregation, and contraction. This innovative approach seeks to improve the reliability and reproducibility of platelet function testing and potentially...
This $718,854 federal Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to Versiti Wisconsin, Inc., a non-profit blood center and research organization. The award supports research to elucidate the cellular mechanisms governing the non-conventional signaling function of the α5β1 integrin in the formation of tunneling nanotubes (TNTs) and inflammation in blood and endothelial cells. The...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $438,682 to The Johns Hopkins University to conduct a multi-center observational study on silent cerebral infarction (SCI) in patients with immune thrombotic thrombocytopenic purpura (iTTP). The study aims to elucidate the natural history of SCI, establish the incidence and risk factors for new SCI and stroke during iTTP remission, and...